Table 2.
Variables measured by the continuous glucose monitoring system and plaque characteristics detected by optical coherence tomography
| Variables | Change in the vildagliptin group (6 months—baseline) | Change in the control group (6 months—baseline) | Difference between mean change | ||
|---|---|---|---|---|---|
| Difference | 95% confidence interval | p Value | |||
| Variables measured by the continuous glucose monitoring system | |||||
| (n = 10) | (n = 10) | ||||
| MAGE, mg/dl | − 20.2 ± 18.0 | 2.6 ± 12.7 | − 18.8 | − 30.8 to − 6.8 | 0.0064 |
| Time in hyperglycemia, hours | − 7.9 ± 14.1 | − 0.8 ± 10.2 | − 3.7 | − 11.4 to 3.9 | 0.350 |
| Time in hypoglycemia, hours | − 0.8 ± 3.5 | 4.7 ± 15.4 | − 6.1 | − 15.3 to 3.1 | 0.209 |
| Mean BS, mg/dl | − 3.3 ± 17.3 | 0.4 ± 13.3 | 0.3 | − 9.5 to 10.0 | 0.960 |
| Maximum BS, mg/dl | − 36.3 ± 65.8 | 1.2 ± 37.6 | − 11.5 | − 43.1 to 20.0 | 0.482 |
| Minimum BS, mg/dl | 5.5 ± 24.8 | 7.6 ± 23.1 | 4.8 | − 10.3 to 20.0 | 0.538 |
| HOMA R | 0.6 ± 0.7 | 0.1 ± 1.0 | 0.5 | − 0.3 to 1.3 | 0.243 |
| Plaque characteristics detected by optical coherence tomography | |||||
| (n = 22) | (n = 25) | ||||
| MLA, mm2 | 0.62 ± 1.94 | − 0.29 ± 0.65 | 0.99 | − 0.26 to 2.23 | 0.120 |
| Lipid length, mm | − 0.10 ± 1.40 | − 0.52 ± 2.37 | 0.03 | − 1.28 to 1.34 | 0.963 |
| Lipid arc, ° | − 9.00 ± 25.57 | 15.87 ± 16.82 | − 22.82 | − 40.56 to − 5.09 | 0.017 |
| Minimum FCT, μm | 35.75 ± 50.80 | − 15.19 ± 25.02 | 42.73 | 15.34 to 70.12 | 0.0022 |
Mean ± standard deviation (n) for continuous variables
Time in hyperglycemia was defined as the time when blood glucose levels were above 140 mg/dl. Time in hypoglycemia was defined as the time when blood glucose levels were under 70 mg/dl
BS = blood sugar; FCT = fibrous cap thickness; HOMA R = homeostasis model assessment ratio; MAGE = mean amplitude of glycemic excursion; MLA = minimum lumen area